Aevi Genomic Medicine Inc (NASDAQ:GNMX) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 371,900 shares, a growth of 133.2% from the April 30th total of 159,500 shares. Based on an average daily volume of 1,680,000 shares, the short-interest ratio is presently 0.2 days. Approximately 1.1% of the company’s stock are short sold.

A hedge fund recently raised its stake in Aevi Genomic Medicine stock. Vanguard Group Inc raised its stake in Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 1.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 986,590 shares of the biotechnology company’s stock after buying an additional 16,138 shares during the period. Vanguard Group Inc owned about 1.52% of Aevi Genomic Medicine worth $1,214,000 at the end of the most recent quarter. 6.35% of the stock is owned by institutional investors.

GNMX stock traded up $0.01 during trading on Monday, reaching $0.18. The stock had a trading volume of 696 shares, compared to its average volume of 608,672. The stock has a market cap of $11.41 million, a P/E ratio of -0.35 and a beta of 0.90. Aevi Genomic Medicine has a one year low of $0.15 and a one year high of $1.40. The stock has a 50 day moving average price of $0.20.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Featured Article: The role of implied volatility with call option volume

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.